DS-8201a
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Aug 25, 2017 → May 6, 2024
NCT ID
NCT03248492About DS-8201a
DS-8201a is a phase 2 stage product being developed by Daiichi Sankyo for Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03248492. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04132960 | Phase 2 | Completed |
| NCT03368196 | Phase 1 | Completed |
| NCT03384940 | Phase 2 | Completed |
| NCT03366428 | Phase 1 | Completed |
| NCT03248492 | Phase 2 | Terminated |
Competing Products
20 competing products in Breast Cancer